AMOYTOP(SH:688278)2022-10-25 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥428,328,301.48, representing a year-on-year increase of 25.78%[4] - The net profit attributable to shareholders for Q3 2022 was ¥66,750,969.95, reflecting a year-on-year growth of 20.09%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥92,602,380.26, an increase of 37.43% compared to the same period last year[4] - Operating profit for Q3 2022 was ¥312,075,068.15, up from ¥191,556,085.91 in Q3 2021, reflecting a growth of approximately 63%[19] - Net profit for Q3 2022 was ¥200,405,087.53, compared to ¥127,688,290.01 in Q3 2021, representing an increase of about 57%[20] - Total operating revenue for the first three quarters of 2022 reached ¥1,143,196,090.93, a significant increase of 41% compared to ¥809,788,878.19 in the same period of 2021[18] Research and Development - The total R&D investment for Q3 2022 was ¥67,350,996.36, which is a significant increase of 73.25% year-on-year[5] - The R&D investment accounted for 15.72% of operating revenue in Q3 2022, up by 4.30 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2022 totaled ¥101,007,835.52, which is an increase of 77% from ¥56,853,312.07 in the same period of 2021[18] Assets and Equity - The total assets at the end of Q3 2022 were ¥1,618,644,330.47, marking a 13.65% increase from the end of the previous year[5] - The equity attributable to shareholders at the end of Q3 2022 was ¥1,320,985,497.82, which is a 13.75% increase year-on-year[5] - The company's total equity attributable to shareholders reached ¥1,320,985,497.82 in Q3 2022, up from ¥1,161,260,410.29 in Q3 2021, indicating an increase of about 14%[17] - The company's retained earnings increased to ¥471,494,669.57 in Q3 2022, up from ¥311,769,582.04 in Q3 2021, marking a growth of around 51%[17] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥226,767,086.97 for the year-to-date, an increase of 29.62% compared to the previous year[4] - Operating cash inflow for Q3 2022 was CNY 1,185,427,484.98, an increase from CNY 866,525,074.04 in Q3 2021, representing a growth of approximately 36.7%[21] - Cash received from sales and services was CNY 1,149,106,571.38, significantly higher than CNY 860,312,564.53 in the same quarter last year, indicating a growth of approximately 33.5%[21] - Net cash outflow from investing activities was CNY -121,376,321.85, compared to CNY -27,556,413.41 in the previous year, indicating a decline in investment performance[22] - Cash inflow from investment activities totaled CNY 528,631,695.44, down from CNY 684,118,316.80, indicating a decrease of about 22.8%[22] Liabilities and Costs - The company's total liabilities reached RMB 297,658,832.65, an increase from RMB 262,914,519.78 at the end of 2021, which is an increase of about 13.2%[16] - Cash paid to employees increased to CNY 220,746,152.98 from CNY 157,931,366.74, reflecting a rise of about 39.7% in labor costs[21] - Cash paid for taxes rose to CNY 97,533,628.07, up from CNY 58,637,242.68, representing an increase of approximately 66.2%[21] - The total operating costs for the first three quarters of 2022 were ¥868,242,199.05, which is an increase of 38% from ¥629,500,203.70 in the same period of 2021[18] Donations and Social Responsibility - The company's cash donations during the reporting period included RMB 5.25 million for the "China Chronic Hepatitis B Clinical Cure Project" and RMB 11 million for the "China Reducing Hepatocellular Carcinoma Incidence Research Project," totaling RMB 16.25 million in donations[12] - The company plans to donate up to 200,000 units of Peginterferon to support public welfare projects related to viral hepatitis patients over the next two years[12]